[go: up one dir, main page]

WO2005048979A3 - Pharmaceutical composition having casing with multiple micro tablets - Google Patents

Pharmaceutical composition having casing with multiple micro tablets Download PDF

Info

Publication number
WO2005048979A3
WO2005048979A3 PCT/IN2004/000307 IN2004000307W WO2005048979A3 WO 2005048979 A3 WO2005048979 A3 WO 2005048979A3 IN 2004000307 W IN2004000307 W IN 2004000307W WO 2005048979 A3 WO2005048979 A3 WO 2005048979A3
Authority
WO
WIPO (PCT)
Prior art keywords
casing
controlling agent
rate controlling
pharmaceutical composition
multiple micro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2004/000307
Other languages
French (fr)
Other versions
WO2005048979A2 (en
Inventor
Vinod Kumar Gupta
Navin Vaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torrent Pharmaceuticals Ltd
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of WO2005048979A2 publication Critical patent/WO2005048979A2/en
Anticipated expiration legal-status Critical
Publication of WO2005048979A3 publication Critical patent/WO2005048979A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A modified release pharmaceutical composition is disclosed. The composition consists of casing comprising at least two micro tablets, which are coated with rate controlling agent(s) optionally in combination with auxiliary pharmaceutical excepient(s), wherein each micro tablet comprises core particles comprising pharmaceutical active ingredient and rate controlling agent(s), the said core particles optionally coated with rate controlling agent(s), wherein the ratio of pharmaceutical active ingredient to total rate controlling agent(s) ranges between 1 : 0.1 to 1 : 100 of each micro tablet.
PCT/IN2004/000307 2003-10-06 2004-10-04 Pharmaceutical composition having casing with multiple micro tablets Ceased WO2005048979A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1045MU2003 2003-10-06
IN1045/MUM/2003 2003-10-06

Publications (2)

Publication Number Publication Date
WO2005048979A2 WO2005048979A2 (en) 2005-06-02
WO2005048979A3 true WO2005048979A3 (en) 2006-04-27

Family

ID=34611199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000307 Ceased WO2005048979A2 (en) 2003-10-06 2004-10-04 Pharmaceutical composition having casing with multiple micro tablets

Country Status (1)

Country Link
WO (1) WO2005048979A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106727402A (en) * 2016-12-23 2017-05-31 江苏苏南药业实业有限公司 A kind of preparation method of the tablet of hydrochloric MOXIFLOXACIN

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005048293A1 (en) * 2005-10-08 2007-04-12 Sanofi-Aventis Deutschland Gmbh Retard formulation for pralnacasan
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
HUE029173T2 (en) * 2006-04-26 2017-02-28 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
EP2175722A4 (en) * 2007-07-12 2010-08-25 Tragara Pharmaceuticals Inc PATIENT SELECTION AND THERAPEUTIC METHODS USING PROSTAGLANDIN METABOLISM MARKERS
WO2009009778A1 (en) 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
CN102065855A (en) 2008-04-17 2011-05-18 赛诺菲-安万特 Use of dronedarone in the preparation of a medicament for preventing hospitalization or death due to cardiovascular disease
GR1006406B (en) * 2008-05-06 2009-05-26 Specifar Abee ���������� ������� ��� ������������� ��������� Sustained release microtablets for tolterodine tartrate.
WO2010044097A2 (en) * 2008-09-15 2010-04-22 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
CN101496789B (en) * 2009-03-17 2012-12-19 重庆莱美药业股份有限公司 Sitafloxacin sustained-release pellet and preparation method thereof
CN101596195B (en) * 2009-05-15 2011-09-28 迪沙药业集团有限公司 Oral medicine composite for reducing blood pressure
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2503996A2 (en) 2009-11-26 2012-10-03 USV Limited Controlled release pharmaceutical compositions of galantamine
WO2011102505A1 (en) * 2010-02-22 2011-08-25 第一三共株式会社 Sustained-release solid preparation for oral use
WO2011102504A1 (en) 2010-02-22 2011-08-25 第一三共株式会社 Sustained-release solid preparation for oral use
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
US20130142849A1 (en) * 2010-08-17 2013-06-06 Lupin Limited Controlled release formulations of dronedarone
FR2967067A1 (en) * 2010-11-10 2012-05-11 Sanofi Aventis PHARMACEUTICAL COMPOSITION AND GALENIC FORM BASED ON DRONEDARONE AND PROCESS FOR PREPARING THE SAME
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
KR101378973B1 (en) * 2012-04-13 2014-03-28 한미약품 주식회사 Hard capsule complex formulations comprising a multi-dose unit tablet of a near-spherical form and method for preparing the same
EP2893928B1 (en) 2012-09-03 2018-10-24 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
CN102846571A (en) * 2012-09-29 2013-01-02 南京正科制药有限公司 Esomeprazole magnesium micro-tablet
UA120249C2 (en) 2013-02-13 2019-11-11 Редхілл Байофарма Лтд. Pharmaceutical compositions for the treatment of helicobacter pylori
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2016147108A1 (en) * 2015-03-17 2016-09-22 Hetero Research Foundation Pharmaceutical compositions of dimethyl fumarate
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN106822021A (en) * 2016-12-23 2017-06-13 江苏苏南药业实业有限公司 A kind of moxifloxacin hydrochloride controlled release tablet
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
CN112716916A (en) * 2019-10-14 2021-04-30 蒋海松 Sustained-release micro-tablet capsule of 5-hydroxytryptamine, norepinephrine and dopamine reuptake inhibitor and preparation method thereof
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
CN112294799A (en) * 2020-11-17 2021-02-02 中山万汉制药有限公司 Anti-influenza application of orlistat and orlistat composition
CN117462516B (en) * 2023-08-04 2024-08-30 青岛海洋生物医药研究院 Sustained-release pellet, preparation method thereof and pellet tablet thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4139118A1 (en) * 1991-11-28 1993-06-03 Schwabe Willmar Gmbh & Co Slow-release micro-tablets contg. dry extract of vegetable origin - e.g. gingkolide B or aesculus extract and glyceride, fatty alcohol and/or wax as lipophilic auxiliary
EP0797991A1 (en) * 1996-03-25 1997-10-01 American Home Products Corporation Extended release formulation containing venlafaxine
EP1228763A1 (en) * 2001-02-05 2002-08-07 Valpharma S.A. Multiparticulate formulations of lithium salts for once-a-day administration
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
WO2005009414A1 (en) * 2003-07-30 2005-02-03 Pharmathen S.A. Sutained release formulation for venlafaxine hydrochloride

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4139118A1 (en) * 1991-11-28 1993-06-03 Schwabe Willmar Gmbh & Co Slow-release micro-tablets contg. dry extract of vegetable origin - e.g. gingkolide B or aesculus extract and glyceride, fatty alcohol and/or wax as lipophilic auxiliary
EP0797991A1 (en) * 1996-03-25 1997-10-01 American Home Products Corporation Extended release formulation containing venlafaxine
EP1228763A1 (en) * 2001-02-05 2002-08-07 Valpharma S.A. Multiparticulate formulations of lithium salts for once-a-day administration
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
WO2005009414A1 (en) * 2003-07-30 2005-02-03 Pharmathen S.A. Sutained release formulation for venlafaxine hydrochloride

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106727402A (en) * 2016-12-23 2017-05-31 江苏苏南药业实业有限公司 A kind of preparation method of the tablet of hydrochloric MOXIFLOXACIN

Also Published As

Publication number Publication date
WO2005048979A2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
WO2005048979A3 (en) Pharmaceutical composition having casing with multiple micro tablets
AU2003274680A1 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
EP1293196A3 (en) Pharmaceutical composition comprising doxazosin
WO2005048923A3 (en) Extended release venlafaxine formulation
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
WO2007052125A3 (en) Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
AU2001256184A1 (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
AU2001262011A1 (en) A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
AU2003276131A1 (en) A dry powder oligonucleotide formulation, preparation and its uses
WO2003066030A3 (en) Pharmaceutical tablet
WO2006035418A3 (en) Microcapsules comprising a methylxanthine and a corticosteroid
CA2199778A1 (en) Extended release formulation of venlafaxine
WO2003000226A3 (en) Pharmaceutical compositions containing polymer and drug assemblies
IL231576A (en) Adamantyl-acetamide derivatives, pharmaceutical compositions comprising same and use thereof in the manufacture of medicaments
IL220888A0 (en) 3,10 and 12 a substituted tetracyline compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL163366A (en) Glucocorticoid mimetics, pharmaceutical compositions thereof and uses thereof for the preparation of pharmaceutical compositions
IL219671A0 (en) 1,2- benzoxazoles and use thereof in the preparation of a medicament
AU2002223127A1 (en) Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
WO2001047498A3 (en) Hydrogel-driven layered drug dosage form comprising sertraline
AU2000273085A1 (en) Sustained release pharmaceutical compositions containing metformin and method ofits production
WO2007041367A3 (en) Oral composition containing a salivation inducing agent
AU2003257176A1 (en) Delayed release anti-fungal product, use and formulation thereof
EP1831240B8 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
AU2003222823A1 (en) Physiologically compatible, phospholipid-containing, stable and hard matrix
AU2003272903A1 (en) Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase